Patient-specific factors that influence choice include: Concurrent diabetes : Patients with type 2 diabetes may have broader access through NHS prescribing pathways BMI and weight loss goals : Higher BMI patients may benefit from agents with greater weight loss efficacy Tolerability : Previous experience with gastrointestinal side effects may guide selection Injection preference : Some patients strongly prefer weekly over daily injections, or oral over injectable formulations Cardiovascular disease : Certain GLP-1 agonists have proven cardiovascular benefits, which may be relevant for high-risk patients Ultimately, the choice should be individualised through shared decision-making between patient and clinician, considering the available evidence, licensed indications, local prescribing policies, and patient preferences
:max_bytes(150000):strip_icc()/Common-Symptoms-From-Taking-a-GLP-1-And-How-to-Manage-Them-9e5bb7cee0484522a50dd9d7ce954cc4.jpg)
Step 1: Determine Your Eligibility Quick Self-Assessment: Calculate Your BMI: BMI = (Weight in pounds / (Height in inches)) 703 Or use this quick reference: 54, 175 lbs = BMI 30 56, 186 lbs = BMI 30 58, 197 lbs = BMI 30 510, 209 lbs = BMI 30 You likely qualify if: BMI 30, OR BMI 27-29.9 + diabetes, hypertension, high cholesterol, or sleep apnea Age 18+ (12+ for some medications) No personal/family history of thyroid cancer Not pregnant or planning pregnancy If you meet these criteria, proceed to Step 2
Open research questions Important gaps remain in the literature
CVS Caremark (Aetna's PBM) removed Zepbound from standard formularies in July 2025including for OSA [9] Self-funded employers can override this decision and keep Zepbound covered Formulary exception requests are still possible with strong medical documentation To determine your exact coverage, check directly with Aetna
This ensures a delicious, healthy, and safe dieting approach that complements the appetite-suppressing effects of GLP-1 injections, helping you stay on track with your weight-loss journey